{"id":{"repo_id":"york","oai_identifier":"oai:yorkspace.library.yorku.ca:10315/40637"},"canonical_url":"https://search.dev.ndltd.org/etd/york/oai:yorkspace.library.yorku.ca:10315/40637","repository":{"repo_id":"york","name":"York University","base_url":"https://yorkspace.library.yorku.ca/oai/request"},"display":{"title":"Impacts of Empagliflozin (EMPA) Treatment on Skeletal Muscle Microvasculature in Type 1 Diabetic Rats","abstract":"In individuals with type 1 diabetes (T1D) and models of the disease, hyperglycemia is associated with microvascular complications, including reduced capillary ratio in skeletal muscle (SM). We investigated whether a blood glucose lowering drug, empagliflozin (EMPA), has any impact on the microvasculature in SM. T1D was induced in eight-week-old male rats using streptozotocin (65 mg/kg, n=21). Twenty-one rats were given daily insulin and 11 of 21 rats also consumed EMPA (30 mg/kg/day) for 14 days. Twelve healthy non-diabetic rats served as controls. Capillary content and angiogenic factors were assessed in three separate leg muscles. EMPA+insulin treated rats exhibited better glycemic control, but capillary to fibre ratio and VEGFa mRNA was not impacted by EMPA+insulin treatment in the tibialis anterior. PECAM mRNA and VEGFa protein expression was also not impacted by EMPA+insulin treatment. EMPA has no obvious impact on the vasculature of SM in type 1 diabetic rodents.","abstract_html":"In individuals with type 1 diabetes (T1D) and models of the disease, hyperglycemia is associated with microvascular complications, including reduced capillary ratio in skeletal muscle (SM). We investigated whether a blood glucose lowering drug, empagliflozin (EMPA), has any impact on the microvasculature in SM. T1D was induced in eight-week-old male rats using streptozotocin (65 mg/kg, n=21). Twenty-one rats were given daily insulin and 11 of 21 rats also consumed EMPA (30 mg/kg/day) for 14 days. Twelve healthy non-diabetic rats served as controls. Capillary content and angiogenic factors were assessed in three separate leg muscles. EMPA+insulin treated rats exhibited better glycemic control, but capillary to fibre ratio and VEGFa mRNA was not impacted by EMPA+insulin treatment in the tibialis anterior. PECAM mRNA and VEGFa protein expression was also not impacted by EMPA+insulin treatment. EMPA has no obvious impact on the vasculature of SM in type 1 diabetic rodents.","abstract_has_math":false,"creators":["El-Zahed, Maya"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Riddell, Michael C."],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-12-14","date_published":"2022-12-14","updated_at":"2026-07-24T06:33:55Z","subjects":["Health sciences","Physiology"],"languages":["en"],"rights":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10315/40637","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Riddell, Michael C."]},{"key":"dc:creator","label":"Author","values":["El-Zahed, Maya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2022-12-14T16:23:35Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2022-12-14T16:23:35Z"]},{"key":"dc:date.issued","label":"Date","values":["2022-12-14"]},{"key":"dc:type","label":"Dc Type","values":["Electronic Thesis or Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Health sciences","Physiology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10315/40637"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["In individuals with type 1 diabetes (T1D) and models of the disease, hyperglycemia is associated with microvascular complications, including reduced capillary ratio in skeletal muscle (SM). We investigated whether a blood glucose lowering drug, empagliflozin (EMPA), has any impact on the microvasculature in SM. T1D was induced in eight-week-old male rats using streptozotocin (65 mg/kg, n=21). Twenty-one rats were given daily insulin and 11 of 21 rats also consumed EMPA (30 mg/kg/day) for 14 days. Twelve healthy non-diabetic rats served as controls. Capillary content and angiogenic factors were assessed in three separate leg muscles. EMPA+insulin treated rats exhibited better glycemic control, but capillary to fibre ratio and VEGFa mRNA was not impacted by EMPA+insulin treatment in the tibialis anterior. PECAM mRNA and VEGFa protein expression was also not impacted by EMPA+insulin treatment. EMPA has no obvious impact on the vasculature of SM in type 1 diabetic rodents."]},{"key":"dc:title","label":"Title","values":["Impacts of Empagliflozin (EMPA) Treatment on Skeletal Muscle Microvasculature in Type 1 Diabetic Rats"]}]}],"canonical_facts":{"dc:contributor.advisor":["Riddell, Michael C."],"dc:creator":["El-Zahed, Maya"],"dc:date.accessioned":["2022-12-14T16:23:35Z"],"dc:date.available":["2022-12-14T16:23:35Z"],"dc:date.issued":["2022-12-14"],"dc:description.abstract":["In individuals with type 1 diabetes (T1D) and models of the disease, hyperglycemia is associated with microvascular complications, including reduced capillary ratio in skeletal muscle (SM). We investigated whether a blood glucose lowering drug, empagliflozin (EMPA), has any impact on the microvasculature in SM. T1D was induced in eight-week-old male rats using streptozotocin (65 mg/kg, n=21). Twenty-one rats were given daily insulin and 11 of 21 rats also consumed EMPA (30 mg/kg/day) for 14 days. Twelve healthy non-diabetic rats served as controls. Capillary content and angiogenic factors were assessed in three separate leg muscles. EMPA+insulin treated rats exhibited better glycemic control, but capillary to fibre ratio and VEGFa mRNA was not impacted by EMPA+insulin treatment in the tibialis anterior. PECAM mRNA and VEGFa protein expression was also not impacted by EMPA+insulin treatment. EMPA has no obvious impact on the vasculature of SM in type 1 diabetic rodents."],"dc:identifier.uri":["http://hdl.handle.net/10315/40637"],"dc:language":["en"],"dc:rights":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."],"dc:subject":["Health sciences","Physiology"],"dc:title":["Impacts of Empagliflozin (EMPA) Treatment on Skeletal Muscle Microvasculature in Type 1 Diabetic Rats"],"dc:type":["Electronic Thesis or Dissertation"]},"updated_at":"2026-07-24T06:33:55Z"}